416 related articles for article (PubMed ID: 28841377)
1. Role of Sporadic Parkinson Disease Associated Mutations A18T and A29S in Enhanced α-Synuclein Fibrillation and Cytotoxicity.
Kumar S; Jangir DK; Kumar R; Kumari M; Bhavesh NS; Maiti TK
ACS Chem Neurosci; 2018 Feb; 9(2):230-240. PubMed ID: 28841377
[TBL] [Abstract][Full Text] [Related]
2. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations.
Sahay S; Ghosh D; Singh PK; Maji SK
Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727
[TBL] [Abstract][Full Text] [Related]
3. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
[TBL] [Abstract][Full Text] [Related]
4. Analysis of sheep α-synuclein provides a molecular strategy for the reduction of fibrillation.
Bickle L; Hopwood JJ; Karageorgos L
Biochim Biophys Acta Proteins Proteom; 2017 Mar; 1865(3):261-273. PubMed ID: 28007442
[TBL] [Abstract][Full Text] [Related]
5. Sporadic SNCA mutations A18T and A29S exhibit variable effects on protein aggregation, cell viability and oxidative stress.
Joshi N; Sarhadi TR; Raveendran A; Nagotu S
Mol Biol Rep; 2023 Jul; 50(7):5547-5556. PubMed ID: 37155014
[TBL] [Abstract][Full Text] [Related]
6. Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of α-synuclein.
Rutherford NJ; Moore BD; Golde TE; Giasson BI
J Neurochem; 2014 Dec; 131(6):859-67. PubMed ID: 24984882
[TBL] [Abstract][Full Text] [Related]
7. The effects of the novel A53E alpha-synuclein mutation on its oligomerization and aggregation.
Lázaro DF; Dias MC; Carija A; Navarro S; Madaleno CS; Tenreiro S; Ventura S; Outeiro TF
Acta Neuropathol Commun; 2016 Dec; 4(1):128. PubMed ID: 27938414
[TBL] [Abstract][Full Text] [Related]
8. The newly discovered Parkinson's disease associated Finnish mutation (A53E) attenuates α-synuclein aggregation and membrane binding.
Ghosh D; Sahay S; Ranjan P; Salot S; Mohite GM; Singh PK; Dwivedi S; Carvalho E; Banerjee R; Kumar A; Maji SK
Biochemistry; 2014 Oct; 53(41):6419-21. PubMed ID: 25268550
[TBL] [Abstract][Full Text] [Related]
9. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional mutagenesis by 8-oxodG in α-synuclein aggregation and the pathogenesis of Parkinson's disease.
Basu S; Je G; Kim YS
Exp Mol Med; 2015 Aug; 47(8):e179. PubMed ID: 26315598
[TBL] [Abstract][Full Text] [Related]
11. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein.
Li J; Uversky VN; Fink AL
Biochemistry; 2001 Sep; 40(38):11604-13. PubMed ID: 11560511
[TBL] [Abstract][Full Text] [Related]
12. Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation.
Lázaro DF; Rodrigues EF; Langohr R; Shahpasandzadeh H; Ribeiro T; Guerreiro P; Gerhardt E; Kröhnert K; Klucken J; Pereira MD; Popova B; Kruse N; Mollenhauer B; Rizzoli SO; Braus GH; Danzer KM; Outeiro TF
PLoS Genet; 2014 Nov; 10(11):e1004741. PubMed ID: 25393002
[TBL] [Abstract][Full Text] [Related]
13. Novel A18T and pA29S substitutions in α-synuclein may be associated with sporadic Parkinson's disease.
Hoffman-Zacharska D; Koziorowski D; Ross OA; Milewski M; Poznanski JA; Jurek M; Wszolek ZK; Soto-Ortolaza A; Awek JAS; Janik P; Jamrozik Z; Potulska-Chromik A; Jasinska-Myga B; Opala G; Krygowska-Wajs A; Czyzewski K; Dickson DW; Bal J; Friedman A
Parkinsonism Relat Disord; 2013 Nov; 19(11):1057-1060. PubMed ID: 23916651
[TBL] [Abstract][Full Text] [Related]
14. Lack of pathogenic potential of peripheral α-synuclein aggregates from Parkinson's disease patients.
Recasens A; Carballo-Carbajal I; Parent A; Bové J; Gelpi E; Tolosa E; Vila M
Acta Neuropathol Commun; 2018 Feb; 6(1):8. PubMed ID: 29422109
[TBL] [Abstract][Full Text] [Related]
15. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
Conway KA; Harper JD; Lansbury PT
Nat Med; 1998 Nov; 4(11):1318-20. PubMed ID: 9809558
[TBL] [Abstract][Full Text] [Related]
16. Copper Binding and Subsequent Aggregation of α-Synuclein Are Modulated by N-Terminal Acetylation and Ablated by the H50Q Missense Mutation.
Mason RJ; Paskins AR; Dalton CF; Smith DP
Biochemistry; 2016 Aug; 55(34):4737-41. PubMed ID: 27517125
[TBL] [Abstract][Full Text] [Related]
17. Initiation and propagation of α-synuclein aggregation in the nervous system.
Hijaz BA; Volpicelli-Daley LA
Mol Neurodegener; 2020 Mar; 15(1):19. PubMed ID: 32143659
[TBL] [Abstract][Full Text] [Related]
18. C-terminal truncation exacerbates the aggregation and cytotoxicity of α-Synuclein: A vicious cycle in Parkinson's disease.
Ma L; Yang C; Zhang X; Li Y; Wang S; Zheng L; Huang K
Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3714-3725. PubMed ID: 30290273
[TBL] [Abstract][Full Text] [Related]
19. Neurotoxic or neuroprotective: Post-translational modifications of α-synuclein at the cross-roads of functions.
Gadhavi J; Patel M; Bhatia D; Gupta S
Biochimie; 2022 Jan; 192():38-50. PubMed ID: 34582997
[TBL] [Abstract][Full Text] [Related]
20. Physicochemical characterization of the G51D mutation of α-synuclein that is responsible for its severe cytotoxicity.
Murata T; Tochio N; Utsunomiya-Tate N
Neurosci Lett; 2021 Aug; 760():136077. PubMed ID: 34161822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
